Sterilizing bacteriophage products using supercritical carbon dioxide
By using supercritical carbon dioxide and polymer layers or microcapsules to protect phages, the problem of phages being heat-sensitive in the prior art is solved, effective disinfection and bacterial control are achieved, and the safety and activity of the product are ensured.
Patent Information
- Application Number
- CN202080006478.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-06-20
- Filing Date
- 2020-06-18
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2040-06-18
AI Technical Summary
The prior art is difficult to effectively sterilize medical devices and products containing phages, especially since phages and polymers are heat sensitive and prone to degradation, resulting in the inability of conventional sterilization methods to achieve effective disinfection without reducing activity.
Supercritical carbon dioxide (scCO2) is used as the disinfectant fluid, combined with appropriate pressure and temperature conditions, and through the protection of polymer layers or microcapsules, the biological activity of the bacteriophage is not degraded and the bacterial content in the target environment is effectively reduced.
Effective disinfection of bacteriophages is achieved, sufficient activity is maintained to fight targeted bacteria, while avoiding bacterial contamination, and meeting the sterilization standards of medical devices.
Smart Images

Figure CN113164636B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the general field of bacteriophages, and more particularly to the sterilization of bacteriophage products using supercritical carbon dioxide and corresponding sterilized bacteriophage products. Background Art
[0002] Antimicrobial products utilizing bacteriophages, endolysins, and other biological solutions provide alternatives to antibiotics to combat undesirable bacteria, such as targeting antibiotic resistant bacteria (AMR). In many applications, it may be advantageous to deliver bacteriophages using an appropriate delivery system. For many applications, such as in medical treatments for humans and animals, these delivery systems using uniquely applicable technologies that allow controlled release of bacteriophages require terminal sterilization. In some cases, bacteriophages are embedded in or otherwise associated with bioabsorbable polymers. As the polymer degrades in vivo, the bacteriophages can be released at a controlled rate.
[0003] Microbial decontamination is important for manufacturing pharmaceutical and medical device products. Sterilizing medical devices containing bacteriophages presents a particular challenge to existing medical sterilization technologies because both polymers and bacteriophages are heat sensitive and susceptible to degradation and inactivation. Therefore, bacteriophages cannot usually be effectively sterilized using conventional sterilization methods without significantly reducing activity.
[0004] Therefore, there is a need to provide new and improved methods and apparatus for sterilizing products containing bacteriophage. Summary of the invention
[0005] In a broad aspect, a method is provided for producing a disinfection product comprising a bioactive bacteriophage that is infectious to a predetermined bacterium, the disinfection product being usable in a target environment, the method comprising: providing an initial product in which the bioactive bacteriophage is present in an initial amount; and contacting the initial product with a disinfection fluid under disinfection conditions for a disinfection duration to produce the disinfection product from the initial product, the disinfection fluid comprising supercritical carbon dioxide (scCO2); wherein the bioactive bacteriophage is present in the disinfection product in a final amount, and when the disinfection product is used in a target environment, the final amount is effective to produce lysis of the predetermined bacteria to reduce the bacterial content in the target environment.
[0006] A method may also be provided wherein the sterilized product is substantially free of bacterial contamination.
[0007] A method may also be provided wherein the disinfection product is substantially free of microorganisms.
[0008] A method may also be provided wherein providing an initial product wherein the biologically active bacteriophage is present in an initial amount comprises at least partially protecting the biologically active bacteriophage from degradation by scCO2.
[0009] A method may also be provided wherein protecting the biologically active bacteriophage comprises lyophilizing the biologically active bacteriophage.
[0010] A method may also be provided wherein protecting the biologically active bacteriophage comprises encapsulating the biologically active bacteriophage in microcapsules.
[0011] A method may also be provided wherein the microcapsules encapsulate the biologically active bacteriophage within a hydrophobic layer.
[0012] A method may also be provided wherein the microcapsules encapsulate the biologically active bacteriophage within a polymer.
[0013] A method may also be provided wherein protecting the biologically active bacteriophage comprises dispersing the biologically active bacteriophage within a polymer layer.
[0014] A method may also be provided wherein protecting the biologically active bacteriophage comprises immobilizing the biologically active bacteriophage on a polymer.
[0015] A method may also be provided wherein protecting the biologically active bacteriophage comprises adsorbing the biologically active bacteriophage onto a polymer.
[0016] There may also be provided a method wherein the polymer layer is hydrophobic.
[0017] A method may also be provided wherein the polymer is selected from
[0018] (1) poly(esteramide urea) wherein at least one diol, at least one diacid and at least one amino acid are linked together by ester bonds, amide bonds and urea bonds,
[0019] (2) poly(ester polyurethane urea) wherein at least one diol and at least one amino acid are linked together by ester bonds, polyurethane bonds and urea bonds,
[0020] (3) poly(esteramide polyurethaneurea) wherein at least one diol, at least one diacid and at least one amino acid are linked together by ester bonds, amide bonds, polyurethane bonds and urea bonds,
[0021] (4) poly(esteramide polyurethane) wherein at least one diol, at least one diacid and at least one amino acid are linked together by ester bonds, amide bonds and polyurethane bonds,
[0022] (5) poly(ester urea) wherein at least one diol and at least one amino acid are linked together by ester bonds and urea bonds, and
[0023] (6) poly(ester polyurethane) wherein at least one diol and at least one amino acid are linked together via ester bonds and polyurethane bonds,
[0024] Further
[0025] - the at least one diol is a compound of the formula:
[0026] HO-R1-OH, R1 is selected from C2-C 12 Alkylene, C3-C8 cycloalkylene, C3-C 10 Cycloalkyl alkylene, - the at least one diacid is a compound of the formula:
[0027] HO-(CO)-R3-(CO)-OH, R3 is C2-C 12 Alkylene,
[0028] - The at least one amino acid is selected from naturally occurring amino acids and non-naturally occurring amino acids.
[0029] There may also be provided a process wherein the polymer is a poly(esteramide urea) comprising the following two randomly distributed blocks:
[0030]
[0031] in
[0032] -l:m ratio ranges from 0.05:0.95 to 0.95:0.05, l+m=1,
[0033] -R1 is selected from C2-C 12 Alkylene, C3-C8 cycloalkylene, C3-C 10 Cycloalkyl alkylene,
[0034] -R3 is C2-C 12 Alkylene,
[0035] - R2 and R4 are independently selected from the side chains of L-amino acids and D-amino acids, such that the carbon to which R2 or R4 is attached has L or D chirality.
[0036] There can also be provided a process wherein R1 is -(CH2)6-, R3 is -(CH2)8-, and R2 and R4 are both side chains of L-leucine.
[0037] A method may also be provided wherein the sterilizing fluid consists essentially of scCO2.
[0038] A method may also be provided wherein the sterilizing fluid comprises at least 99.9% scCO2.
[0039] A method may also be provided wherein the sterilizing fluid is substantially free of water.
[0040] A method may also be provided wherein the sterilizing fluid contains a biocide additive in addition to the scCO2.
[0041] A method may also be provided wherein the biocide additive is adapted to increase the permeation of CO2 across bacterial cell membranes.
[0042] There may also be provided a method wherein the biocide additive has acidic properties, oxidizing properties, or both acidic and oxidizing properties.
[0043] There may also be provided a method wherein the biocide additive is selected from the group consisting of acetic acid, t-butyl hydroxyperoxide, peracetic acid, ethanol, formic acid and hydrogen peroxide.
[0044] A method may also be provided wherein the sterilizing fluid comprises between about 0.2% to about 10% by volume of the germicide additive.
[0045] A method may also be provided wherein the sterilizing fluid comprises between about 0.5% and about 2% by volume of the germicide additive.
[0046] A method may also be provided wherein the sterilization conditions include a scCO2 pressure between about 8 MPa and about 11 MPa.
[0047] A method may also be provided wherein the sterilization conditions include a scCO2 pressure between about 8 MPa and about 21 MPa.
[0048] A method may also be provided wherein the sterilization conditions include a scCO2 pressure between about 9 MPa and about 10 MPa.
[0049] A method may also be provided wherein the sterilization conditions include exposure to a sterilization fluid at a temperature between about 31°C and about 38°C.
[0050] A method may also be provided wherein the sterilization conditions include exposure to a sterilization fluid at a temperature between about 31°C and about 50°C.
[0051] A method may also be provided wherein the duration of sterilization is between about 30 minutes and about 120 minutes.
[0052] A method may also be provided, wherein the method reduces the phage titer of biologically active phage in the phage-containing portion of the initial product by up to 100-fold such that the final amount is at least 1% of the initial amount.
[0053] A method may also be provided, wherein the method reduces the phage titer of biologically active phage in the phage-containing portion of the initial product by up to 10-fold, such that the final amount is at least 10% of the initial amount.
[0054] In another broad aspect, a method of eliminating or reducing bacterial contamination of a product comprising a composition containing bacteriophage is provided, the method comprising exposing the product to supercritical CO2 (scCO2), wherein the composition containing bacteriophage comprises biologically active bacteriophage after exposure to the scCO2.
[0055] A method may also be provided wherein the composition comprising bacteriophage comprises bacteriophage in solution.
[0056] A method may also be provided wherein the composition comprising bacteriophage comprises lyophilized bacteriophage.
[0057] A method may also be provided wherein the composition comprising bacteriophage comprises bacteriophage dispersed in a polymer.
[0058] A method may also be provided wherein the composition comprising bacteriophage comprises bacteriophage immobilized on a polymer.
[0059] A method may also be provided wherein the composition comprising bacteriophage comprises bacteriophage adsorbed, adhered or otherwise immobilized on a surface.
[0060] There may also be provided a method wherein the product is an implant for implantation in a human or animal body, the surface being an exposed surface of the implant.
[0061] A method may also be provided wherein the composition containing bacteriophage is treated with a bactericide additive in addition to the scCO2.
[0062] A method may also be provided wherein the composition containing bacteriophage is treated simultaneously with a bactericide additive and scCO2.
[0063] A method may also be provided wherein the biocide additive is adapted to increase the permeation of CO2 across bacterial cell membranes.
[0064] There may also be provided a method wherein the biocide additive has acidic properties, oxidizing properties, or both acidic and oxidizing properties.
[0065] There may also be provided a method wherein the biocide additive is selected from the group consisting of acetic acid, t-butyl hydroxyperoxide, peracetic acid, ethanol, formic acid and hydrogen peroxide.
[0066] A method may also be provided wherein the composition containing bacteriophage is treated with scCO2 at between about 9 MPa and about 10 MPa.
[0067] A method may also be provided wherein the composition containing bacteriophage is treated with scCO2 at between about 31°C and about 38°C.
[0068] A method may also be provided wherein the predetermined duration is between about 30 min and about 120 min.
[0069] In another broad aspect, there is also provided a disinfection product obtained by any of the above methods and combinations thereof, which can be used in a target environment to control the growth of predetermined bacteria in the target environment, and the disinfection product comprises: a biologically active bacteriophage that is infectious to the predetermined bacteria.
[0070] It is also possible to provide a sterile product, wherein the sterile product is substantially free of bacterial contamination.
[0071] There may also be provided a disinfectant product, wherein the disinfectant product is selected from the group consisting of a polymer patch, a suspension of polymer microcapsules, an implant comprising a surface coated with a polymer, and a powder composition comprising freeze-dried bacteriophages.
[0072] In another broad aspect, there is provided a method for controlling the growth of predetermined bacteria in a target environment using a biologically active bacteriophage that is infectious to the predetermined bacteria, the method comprising: contacting the above disinfection product with the predetermined bacteria in the target environment, and producing lysis of the predetermined bacteria with the biologically active bacteriophage.
[0073] Advantageously, the proposed method can eliminate or substantially eliminate unwanted microorganisms in a product or a portion of a product while retaining sufficient phage activity to combat the bacteria targeted by the phage.
[0074] In other embodiments, the proposed method is carried out with near supercritical CO2 (i.e., CO2 slightly below the critical temperature, critical pressure, or critical temperature and pressure). For example, in the above-mentioned temperature interval, the lower temperature can be changed from 31°C to 30°C. In addition, the lower pressure limit can be limited to about 7MPa, rather than 8 or 9MPa. In such embodiments, in all claims and embodiments / variants described herein, this near supercritical CO2 can be used instead of supercritical CO2.
[0075] Other objectives, advantages and features of the present invention will become more apparent on reading the following non-restrictive description of a preferred embodiment given by way of example only with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0076] In the attached picture:
[0077] Figure 1Cumulative release of phage cocktails after scCO2 sterilization following refrigerated storage as described in Example 4 is shown. Each bar group shows, from left to right, the titer after 0, 2, 12, 24, and 48 weeks of storage;
[0078] Figure 2 Cumulative release of a K. pneumoniae phage cocktail with accelerated stability at 26°C after scCO2 sterilization as described in Example 4 is shown. Each bar group shows the titer after 0, 2, and 12 weeks of storage from left to right;
[0079] Figure 3 The accelerated stability of Formulation 9 sterilized by scCO2 for 30 minutes as described in Example 5 (stored at 26°C) is shown;
[0080] Figure 4 The accelerated stability of Formulation 10 sterilized by scCO2 for 30 minutes as described in Example 5 (stored at 26°C) is shown;
[0081] Figure 5 The accelerated stability of Formulation 11 sterilized by scCO2 for 30 minutes as described in Example 5 (stored at 26°C) is shown;
[0082] Figure 6 shows the release of phage in a polymer patch treated with scCO2 as described in Example 6 prior to storage of the patch;
[0083] Figure 7 shows the release of phage from a polymer patch treated with scCO2 as described in Example 6 after storage at 4°C for 18 months; and
[0084] Figure 8 The release of phage from polymer patches treated with scCO2 as described in Example 6 after storage at 26°C for 18 months is shown. DETAILED DESCRIPTION
[0085] A fluid is under supercritical conditions when its pressure (P) and temperature (T) are above its pressure and temperature critical points (Pc, Tc). The proposed sterilization process consists of pumping CO2 into a high pressure chamber containing the material to be treated at a selected pressure, temperature and process duration. Optionally, the device can be equipped with an additional pump for injecting sterilant additives with acidic / oxidizing properties that improve the penetration of CO2 through bacterial cell membranes (e.g. acetic acid, tert-butyl hydroxyperoxide, peracetic acid, ethanol, formic acid and hydrogen peroxide).
[0086] The supercritical conditions of CO2 are achieved at mild pressures (Pc = 7.39 MPa) and temperatures (Tc = 31.1 °C), suitable for phages. In addition, the low reactivity of supercritical (sc) CO2 does not lead to significant formation of free radicals and reactive species, which could otherwise alter the structural and mechanical properties of the scaffold and phage. The treatment time is short enough to be practical, ranging from 5 min to 100 h in studies.
[0087] The proposed mechanism of action of scCO2 without binding is the acidification of the bacterial cytoplasm. This requires that CO2 is allowed to dissolve in the aqueous medium containing the microorganism and is converted into the carbonate form, which then dissociates into bicarbonate and hydrogen ions. This has the effect of lowering the pH and damages the cell membrane structure, resulting in an increase in permeability that promotes further penetration of CO2 (Ribiero et al., 2019). The penetration and accumulation of CO2 in the cell allows the cell metabolism to be disturbed by inducing carbonate precipitation, which inactivates decarboxylases and also contributes to the sterilization effect, thereby increasing the extraction of lipids from the bilayer phospholipids of the cell membrane and intracellular structures.
[0088] The use of supercritical CO2 (scCO2) as an alternative to existing sterilization techniques for a wide range of products is disclosed. Specifically, these disclosures relate to techniques for inactivating vegetative bacteria, spore-forming bacteria, fungi, yeasts, and viruses. For bacteriophage products, it is important to emphasize the difference between sterilization and disinfection, the latter term referring to a selective process for eliminating pathogenic microorganisms, and the former term referring to the elimination of all microorganisms and viruses. In the case of bacteriophage products, disinfection methods are required to inactivate harmful bacteria without affecting the viability of the bacteriophage and its release from its encapsulating matrix. In the case of viruses, their inactivation depends on their structure. The use of scCO2 to sterilize products containing bacteriophages in a material that inactivates bacteria but retains bacteriophage activity without affecting the release properties of the matrix is novel and contrary to known techniques. CO2 sterilization is considered to be a very effective method for completely sterilizing a variety of items, and is considered to be very useful because it is considered to completely eliminate all microorganisms, including viruses and bacteriophages. Surprisingly, it has been found that it is possible to protect bacteriophage in certain products from excessive degradation, and the present invention is directed to meeting these needs using relatively mild operating pressures and temperatures and moderate processing times, for example in combination with protecting bacteriophage in the product for sterilization.
[0089] In summary, a method of producing a disinfectant product is proposed, the disinfectant product including a biologically active bacteriophage that is infectious to a predetermined bacteria, the disinfectant product being useful in a target environment. In some embodiments, the disinfectant product is free of bacteria, and in some embodiments is free of viruses and other microorganisms other than the biologically active bacteriophage. In some embodiments, the disinfectant product is substantially free of bacteria and viruses, including bacteriophage, other than the biologically active bacteriophage that is intentionally included in the product in sufficient amounts. Substantially free means that there may be some residual contaminants in some samples processed by the proposed method, but the proposed method meets known industry standards related to the sterilization of devices intended to invasively contact humans and animals (e.g., during surgery or for use as a bandage, among other possibilities).
[0090] A phage is biologically active if it is able to cause lysis of a target bacterium when in contact with it. For example, a biologically active phage will cause bulk lysis to form during a standard phage titration method. In practice, some phage may still be present in a disinfected or sterilized preparation, but in an inactive form, unable to infect bacteria. The proposed method aims to retain sufficient phage activity to combat harmful bacteria when the proposed product is used, for example in the treatment of humans and animals or in the food processing industry, among other possibilities. The phage may be all immediately available when the product is used, or may be gradually released by the product in whole or in part.
[0091] In the proposed method, an initial product is provided in which biologically active bacteriophage is present in an initial amount. If sterilization is not considered, this product will be used directly for its intended use. However, for safety reasons, the proposed product must meet sterilization standards, and the proposed method is implemented so as to meet these sterilization standards while maintaining sufficient activity in the biologically active bacteriophage. The method includes contacting the product with a sterilizing fluid under sterilizing conditions for a period of sterilization duration to produce a sterilized product, the sterilizing fluid comprising supercritical carbon dioxide (scCO2). The biologically active bacteriophage is present in the sterilized product in a final amount, and when the sterilized product is used in a target environment, the final amount is effective to produce lysis of a predetermined bacteria to reduce the bacterial content in the target environment.
[0092] In some embodiments, the sterilized product is substantially free of bacterial contamination or is substantially free of microorganisms.
[0093] In some embodiments, the phage is at least partially protected from degradation by scCO2. Such protection can take a variety of forms, such as encapsulating or immobilizing (e.g., by adsorption, physical adsorption, or covalent bonding) the bioactive phage in a polymer microcapsule, a patch made of a polymer layer, or in or on a polymer layer that coats a product that at least partially includes a different other material, before or after integration with the initial product. The polymer can be hydrophobic and / or amino acid based.
[0094] Non-limiting examples of suitable polymers are selected from the group consisting of
[0095] (1) poly(esteramide urea) wherein at least one diol, at least one diacid and at least one amino acid are linked together by ester bonds, amide bonds and urea bonds,
[0096] (2) poly(ester polyurethane urea) wherein at least one diol and at least one amino acid are linked together by ester bonds, polyurethane bonds and urea bonds,
[0097] (3) poly(esteramide polyurethaneurea) wherein at least one diol, at least one diacid and at least one amino acid are linked together by ester bonds, amide bonds, polyurethane bonds and urea bonds,
[0098] (4) poly(esteramide polyurethane) wherein at least one diol, at least one diacid and at least one amino acid are linked together by ester bonds, amide bonds and polyurethane bonds,
[0099] (5) poly(ester urea) wherein at least one diol and at least one amino acid are linked together by ester bonds and urea bonds, and
[0100] (6) poly(ester polyurethane) wherein at least one diol and at least one amino acid are linked together via ester bonds and polyurethane bonds,
[0101] Further
[0102] The at least one diol is a compound of the formula:
[0103] HO-R1-OH, R1 is selected from C2-C 12 Alkylene, C3-C8 cycloalkylene, C3-C 10 Cycloalkyl alkylene,
[0104] The at least one diacid is a compound of the formula:
[0105] HO-(CO)-R3-(CO)-OH, R3 is C2-C 12 Alkylene,
[0106] The at least one amino acid is selected from naturally occurring amino acids and non-naturally occurring amino acids.
[0107] In some embodiments, the polymer is selected from
[0108] (1) poly(esteramide urea) wherein at least one diol, at least one diacid and at least one amino acid are linked together by ester bonds, amide bonds and urea bonds,
[0109] (2) poly(ester polyurethane urea) wherein at least one diol and at least one amino acid are linked together by ester bonds, polyurethane bonds and urea bonds,
[0110] (3) poly(esteramide polyurethaneurea) wherein at least one diol, at least one diacid and at least one amino acid are linked together by ester bonds, amide bonds, polyurethane bonds and urea bonds, and
[0111] (4) poly(esteramide polyurethane) wherein at least one diol, at least one diacid and at least one amino acid are linked together by ester bonds, amide bonds and polyurethane bonds,
[0112] wherein the at least one diol, the at least one diacid and the at least one amino acid are as defined in the preceding paragraph.
[0113] In some more specific embodiments of the present invention, the polymer is a poly(esteramide urea) comprising the following two randomly distributed blocks:
[0114]
[0115] in
[0116] The l:m ratio ranges from 0.05:0.95 to 0.95:0.05, l+m=1,
[0117] R1 is selected from C2-C 12 Alkylene, C3-C8 cycloalkylene, C3-C 10 Cycloalkyl alkylene,
[0118] R3 is C2-C 12 Alkylene,
[0119] R2 and R4 are independently selected from the side chains of L-amino acids and D-amino acids, such that the carbon to which R2 or R4 is attached has L or D chirality. This polymer is referred to herein as PEAU.
[0120] In the above polymers, in some very specific embodiments of the present invention, one or more of the following is present: R1 is -(CH2)6-, R3 is -(CH2)8-, or R2 and R4 are side chains of L-leucine. These suitable PEAUs are referred to herein as "leucine PEAUs".
[0121] Blends of the above polymers can also be used to prepare the compositions of the present invention. More details about these polymers and other polymers that can be used in the present invention are provided in PCT application PCT / US2016 / 038527 and U.S. patent application 15 / 188,783, the entire contents of which are incorporated herein by reference. This application claims priority to U.S. Provisional Patent Application 62 / 353,658, filed June 23, 2016, the contents of which are incorporated herein by reference in their entirety.
[0122] The encapsulated phage is encapsulated in microcapsules made of suitable polymers, such as PEAU of leucine PEAU, among other possibilities. Due to the two groups, ester and amide, PEAU is biodegradable (ester group) and has good thermal stability and mechanical strength (amide group with strong intermolecular interactions). Incorporation of leucine or other suitable amino acids improves the biocompatibility of the polymer. The biodegradation rate of this polymer can be easily adjusted by changing its exact composition and molecular weight. When forming microcapsules, the release rate of any product incorporated therein can be adjusted by controlling the size and thickness of the microcapsules.
[0123] In some embodiments, such polymers are synthesized by interfacial polycondensation of the di-p-sulfonate salt of monomer L6 bis-(L-leucine)-1,6-hexanediol with triphosgene / sebacyl chloride with a water / dichloromethane system. The use of dichloromethane allows the biocomplex to be used directly for phage incorporation and therefore for microcapsule fabrication. This process is rapid, irreversible, involves two immiscible phases at room temperature and results in high molecular weight polymers. The synthesis of monomer L6 can be performed by condensing L-leucine with 1,6-hexanediol in refluxing cyclohexane (as it is less toxic than solvents such as benzene) in the presence of p-toluenesulfonic acid. Purification includes recrystallization from water, filtration, and vacuum drying.
[0124] In a specific non-limiting embodiment, a water-in-oil-in-water double emulsion solvent is used to make microcapsules, wherein in some embodiments, the phage is added to the secondary emulsion to minimize their contact with the solvent dichloromethane (DCM). DCM can also be replaced by other suitable solvents, such as ethyl acetate, chloroform or other organic solvents.
[0125] The disinfection fluid may consist essentially of scCO2, contain at least 99.9% scCO2, or contain scCO2 of any other suitable purity. In some embodiments, the disinfection fluid is substantially free of water. In some embodiments, in addition to scCO2, the disinfection fluid further comprises a bactericide additive. The bactericide additive promotes disinfection, for example by being suitable for increasing the penetration of CO2 through bacterial cell membranes. For example, the bactericide additive has an acidic property, an oxidizing property, or an acidic property and an oxidizing property. Non-limiting examples of bactericide additives include acetic acid, tert-butyl hydroxyperoxide, peracetic acid, ethanol, formic acid, and hydrogen peroxide.
[0126] It has been found that in some embodiments scCO2 pressures between about 8 MPa and about 11 MPa or between about 9 MPa and about 10 MPa can be particularly useful, although other pressures are also within the scope of the invention. In addition, it has been found that treatment temperatures between about 30°C and about 38°C for about 30 min and about 120 min can be effective in sterilizing the product while maintaining sufficient phage activity, although other values of these parameters can be used in alternative embodiments, such as up to about 21 MPa and about 50°C.
[0127] Disinfection should be gentle enough so that the phage titer (the number of pFU in the phage-containing portion of the product) does not decrease too much. Although a small decrease is acceptable, it is undesirable to reduce to a very small phage titer. In some embodiments, the method reduces the phage titer of biologically active phage by up to 100-fold or 10-fold, so that the final amount is at least 1% or 10% of the initial amount. However, in other embodiments, a greater decrease, such as up to 1000-fold, may be acceptable.
[0128] In use, bacteriophages present in disinfectant products may come into contact with the bacteria they infect and eliminate or reduce the number of those bacteria.
[0129] Example 1: Liquid Staphylococcus aureus phage
[0130] Staphylococcus aureus (S. aureus) phage dissolved in Tris-MgCl2-NaCl (TMN) buffer and 10 6 Staphylococcus aureus phage in TMN buffer contaminated with E. coli at a concentration of CFU / mL was subjected to two supercritical CO2 conditions. Treatment 1 consisted of placing the sample in a reactor vessel heated to 35°C and equilibrated with CO2 at atmospheric pressure. The stirring and agitation mechanism of the CO2 contained in the vessel was started (675 RPM) and the vessel was pressurized to 9.9 MPa and exposed to scCO2 for 2 hours. At the end of the treatment, the stirring was stopped and the sample was removed from the reactor vessel. The 10 6CFU / mL bacteria contaminated (positive control) and untreated controls for each sample type that were not contaminated (negative control). The sterility of the samples was assessed by serial dilution enumeration of bacterial counts after 14 days of sample incubation according to USP standards. For treatment 2, treatment 1 was repeated except that the exposure time to scCO2 was 6 hours. The results showed that when the solution containing buffer and phage was sterilized with both treatments, phage activity was significantly reduced (>4 log).
[0131]
[0132] Table 1: Effect of scCO2 sterilization on S. aureus phages in liquid solution.
[0133] Example 2: Lyophilized Staphylococcus aureus phage
[0134] The lyophilized Staphylococcus aureus phage was 10 6 Lyophilized Staphylococcus aureus phage contaminated with E. coli at CFU / mL concentrations were subjected to two supercritical CO2 conditions. Treatment 1 consisted of placing the lyophilized sample in a reactor vessel heated to 35°C and equilibrated with CO2 at atmospheric pressure. The stirring and agitation mechanism was started (675 RPM) and the vessel was pressurized to 9.9 MPa and exposed to scCO2 for 2 hours. At the end of the treatment, the stirring was stopped and the sample was removed from the reactor vessel. The lyophilized phage was reconstituted by adding 500uL of sterile TMN and vortexed before analysis. The 10 6 CFU / mL bacterial contamination (positive control) and untreated controls for each sample type that were not contaminated (negative control). The sterility of the samples was assessed by serial dilution enumeration of bacterial counts after 14 days of sample incubation according to USP standards. For treatment 2, treatment 1 was repeated except that the exposure time to scCO2 was 6 hours.
[0135]
[0136] Table 2: Effect of scCO2 sterilization on freeze-dried S. aureus phage.
[0137] Example 3: Staphylococcus aureus phage contained in a film biodegradable polymer
[0138] Staphylococcus aureus lyophilized phages were incorporated into a matrix consisting of leucine PEAU. These compounds contain hydrolyzable ester bonds at the monomer stage, which are responsible for the biodegradation of the polymer when incorporated into the polymer backbone. These hydrolyzable ester bonds are carefully monitored to achieve sustained controlled release while the mechanical properties of the polymer are given by the amide functional groups. Each patch additionally contains 10 6 PFU / cm 2The phage particles are immobilized in the wound, allowing a burst release within the first few hours after application, followed by a controlled platform release over several days or more. Once inside the wound, the phage particles attach to their host cells by specifically recognizing receptors on the host surface, and then incorporate the phage nucleic acid into the infected cells. The phage utilizes the host's cellular components to replicate its genome and assemble phage particles. The host cells are eventually lysed by the phage proteins, releasing the progeny phage into the environment, where they can start the lysis cycle again. 2 Uncontaminated patch and 4cm 2 By 10 6 Patches contaminated with E. coli at CFU / mL concentrations were subjected to two supercritical CO2 conditions. Treatment 1 consisted of placing the Tyvek sample in a reactor vessel heated to 35°C and equilibrated with CO2 at atmospheric pressure. The stirring and agitation mechanism was started (675 RPM) and the vessel was pressurized to 9.9 MPa and exposed to scCO2 for 2 hours. At the end of the treatment, the stirring was stopped and the sample was removed from the reactor vessel. The patch was removed from the Tyvek pouch and spread on a lawn of S. aureus bacteria to determine the diameter of the lysis. The 10 6 CFU / mL bacterial contamination (positive control) and untreated controls of each sample type that were not contaminated (negative control) were placed on the same culture dishes and the lysis diameter was determined. After 4 days of culture in TSB medium, the sterility of the samples was evaluated by serial dilution and enumeration of bacterial counts. For treatment 2, treatment 1 was repeated except that the exposure time to scCO2 was 6 hours. The lysis zone of both treatments demonstrated that the phage retained its activity after treatment.
[0139] The specific patch used in this example was about 0.38 mm thick. However, the method of the present invention is applicable to patches having other thicknesses, such as about 0.1 mm to about 1 mm.
[0140] In more detail, formulation 9 was obtained as follows. Formulation 9 is used, for example, to make a biodegradable wound dressing ("artificial skin") composed of a biodegradable polymer PEAU and bacteriophages. Formulation 9 was prepared using the following steps:
[0141] 1. Clean and sterilize the measuring cylinder, funnel, homogenizer and spatula
[0142] 2. Set the workbench in a strictly level position in the chemical fume hood
[0143] 3. Place the clean patch casting assembly (mold) on a horizontal platform.
[0144] 4. Place a small rectangular piece of padding into the die cast assembly.
[0145] 5. Prepare the following:
[0146] 48 mL of polymer solution containing 13% PEAU w / v in DCM
[0147] 24 vials (90-100 mg each) of freeze-dried bacteriophage
[0148] 0.722 g TMN mixture containing: 81.4% Tris-HCl; 12.4% MgSO4 and 6.2% NaCl.
[0149] 6. Use a spatula to place the freeze-dried phage and TMN solids into a cylindrical glass container through a glass funnel.
[0150] 7. Pour the polymer solution into the same container.
[0151] 8. Homogenize at 100 rpm or less while manually moving the cylindrical glass container containing the contents (dried phage + polymer solution) up and down for 30 seconds to homogenize the mixture.
[0152] 9. Pour the homogenized mixture onto the patch casting assembly. Make sure the solution is evenly distributed on the casting surface.
[0153] 10. Partially cover the assembly with a rectangular metal lid and place in a stable environment at room temperature for 2 days to evaporate the DCM under a fume hood
[0154] 11. Dry the patch in a vacuum oven at 40°C (with the cover of the assembly uncovered) for 6 h.
[0155] 12. Once dry, allow the temperature to drop to room temperature before removing the patch from the cast assembly.
[0156]
[0157]
[0158] Table 3: Effect of scCO2 sterilization on Staphylococcus aureus phage contained in biodegradable polymer films.
[0159] Example 4: Effect on the release of a mixture of bacteriophages contained in a thin film biodegradable polymer
[0160] A mixture of Staphylococcus aureus, Pseudomonas aeruginosa (P.aeruginosa) and Klebsiella pneumoniae phages was lyophilized and incorporated into a matrix consisting of leucine PEAU. The mixture was diluted with sucrose 0.1M 1 / 10 and lyophilized (the freeze dryer temperature was set at -40°C) and then placed in a vial, and the vacuum pump was turned on for 3 hours. The temperature was raised to 0°C at a rate of 1°C / min. The temperature was kept stable for 18 hours and then raised to 25°C at a rate of 0.07°C / min. The temperature was kept stable for 6 hours and then dropped to 4°C at a rate of 1°C / min. The lid was closed with a sealing bag, after which the vial was removed from the freeze dryer. 24 bottles of freeze-dried mixture were mixed with 44mL of 13% PEAU in dichloromethane and 0.72g of TMN powder using a high-speed homogenizer. The patch was poured into a 432cm 2 Teflon dish with 3M liner (ScotchPak9741 3.5mm) placed in it. Allow DCM to evaporate overnight under a chemical fume hood. Then dry the patch in a vacuum oven at 40°C for 6h. Place another liner on the dry patch. Then cut the patch into small pieces of 2cm*2cm. Place each small piece in a Tyvek bag with a top cover (A3333 / I73-50). Close the Tyvek bag with tape and label it appropriately. According to the following table, make the 4cm in the Tyvek bag 2 The patch undergoes four supercritical CO2 conditions. Phage release, stability and sterility are performed according to internal standard operating procedures. In brief, each small patch is cut into five small pieces: 3 small pieces are used for release (triplicate) + 2 small pieces are used for sterility testing in tryptic soy agar (TSB) and liquid sodium thioglycolate medium (FTM). Each small patch for release is weighed and standardized to 20-25mg. Each small piece is placed in a 1.5mL tube containing 1mL EMEM+10% FBS. At time points 0, 0.5, 1, 2, 3, 4, 5, 24 hours, sterile tweezers are used to move the patch small pieces to a new 1.5mL tube containing 1mL EMEM+10% FBS. The released phage is titrated according to the following procedure: 100 μL of bacterial daily culture is added to 2.5mL TSB top agar (30g / LTSB+0.7% agar). After a brief vortex, the mixture was immediately poured onto a TSA plate (30 g / LTSB + 15% agar). 10 μL of each dilution was dispensed onto the bacterial layer. The plate was incubated upside down at 37°C for 18 hours. Plaques were counted in the selected dilution (with 10-100 plaques) and the phage titer was calculated according to the following equation: phage titer = number of plaques * 100 / dilution factor. Cumulative release was calculated using the following equation: Cumulative release = total number of phages released for 24 hours / weight of patch small piece.
[0161] Sterility testing was performed using tryptic soy broth (TSB) and liquid sodium thioglycolate medium (FTM) approved by growth promotion testing according to USP7. The samples were incubated in 3 mL of TSB and incubated at 37 ° C for 14 days, and incubated in 3 mL of FTM and incubated at 26 ° C for 14 days. The samples were checked every day for any contamination. If no growth was observed in TSB and FTM after 14 days, the patch was sterile. All patches of all groups remained sterile. Figure 1 It was shown that the released phages were not affected by all treatments when stored at 4°C. Figure 2 Preliminary results obtained for K. pneumoniae subjected to treatments 2, 3 and 4 are shown, showing accelerated stability at 26°C.
[0162] Process 1 Process 2 Process 3 Process 4 Run time 30 minutes 60 minutes 90 minutes 120 minutes Pressurization / decompression time 09:50 / 17:28 13:35 / 18:05 08:59 / 18:05 06:54 / 29:57 Target temperature 35℃ 35℃ 35℃ 35℃ Target pressure 1,436psi 1,436psi 1,436psi 1,436psi Stirring speed 675rpm 675rpm 675rpm 675rpm
[0163] Table 4: scCO2 sterilization procedures according to different exposure times
[0164] Example 5: Bacteriophage contained in polymer microcapsules
[0165] A mixture of Staphylococcus aureus, Pseudomonas aeruginosa and Klebsiella pneumoniae phages is encapsulated in PEAU, and microencapsulation is achieved by water / oil / water double emulsion / solvent evaporation, as described in PCT patent application PCT / IB2017 / 053744 filed on June 22, 2017, the contents of which are incorporated herein by reference in their entirety, with a median size of microcapsules of about 60 μm in diameter. A high-speed homogenizer is used to mix a mixture of phages + 1% polyvinyl alcohol (PVA) (0.8 mL) with a DCM (8 mL) solution of 13% PEAU (formulation #008) for 15 s. The mixture is added dropwise to the mixture + 2% PVA (20 mL) while stirring, and the DCM is evaporated overnight while stirring and the beaker is covered with a watch glass. The final volume of formulation 9 is 22-23 mL. In order to prepare formulation 10, 3% PVA is supplemented in formulation 9. Formulation 10 was stirred overnight at room temperature to ensure complete dissolution of the PVA. Similarly, Formulation 11 was prepared by supplementing Formulation 9 with 0.25 g / mL Poloxamer P407. The formulation was stirred overnight at 4°C to ensure complete dissolution of P407. The microcapsule solution was dispensed into stoppered glass vials. The glass vials were uncapped and packaged in Tyvek TMThe samples were separated by heat sealing in small bags (4-5 samples / bag), which were then introduced into the reactor vessel and exposed to treatments 1 to 4 as previously described. After treatment, the formulation was diluted 1 / 10 in TSB. 100 μL of bacterial daily culture was added to 2.5 mL of TSB top agar (30 g / L TSB + 0.7% agar). The mixture was immediately poured onto a TSA plate (30 g / L TSB + 15% agar) after a brief vortex. 10 μL of each dilution was distributed on the bacterial layer. The plate was incubated upside down at 37°C for 18 hours. Plaques were counted in the selected dilution (with 10-100 plaques) and the phage titer was calculated according to the following equation: phage titer = number of plaques * 100 / dilution factor. Figure 3 , 4 Figures 5 and 5 show that phage activity of all three formulations could be maintained for 112 days when stored at 26°C for accelerated stability.
[0166] Process 1 Run time 30 minutes Pressurization / decompression time 09:50 / 17:28 Target temperature 35℃ Target pressure 1,436psi Stirring speed 675rpm
[0167] Table 5: scCO2 sterilization procedure.
[0168] Therefore, the proposed method not only retains phage activity but also enables the production of a product with a useful shelf life.
[0169] Example 6: Patches containing bacteriophage maintain release kinetics after long-term storage.
[0170] Patches prepared as in Example 4 were stored at either 4°C or 26°C for 18 months to assess whether the scCO2 sterilization process affected the release of phage after long-term storage. This test was performed to ensure that the sterilization process did not induce pre-storage degradation of the polymer matrix or phage, which would then be further damaged upon storage to the extent that the progressive phage release characteristics of the polymer patch were unduly affected. To this end, phage release was assessed as described in Example 4, but rather than assessing only total release, titrations were performed in release medium at various points over the course of a week to assess the kinetics of release.
[0171] Figure 6 Phage titers in culture medium as a function of time before storage are shown. Release kinetics in sterile (30, 60, 90 and 120 min) and non-sterile (CTRL) patches were almost identical. Initial release was rapid (within 2 hours) followed by stabilization after approximately 3 hours. Storage at 4°C for 18 months ( Figure 7 ) did not significantly affect this kinetic in the patches, whether or not they were subjected to scCO2 treatment. Even after 1 week (168 hours) of incubation, a significant amount of phage was still released from the patches. However, storage at 26°C ( Figure 8 ) affected the patch and released about 4 log less after 18 months of storage (when compared with Figure 6 The release was also much smaller than that after storage at 4°C.
[0172] Although the present invention is described above by means of exemplary embodiments of the present invention, it is readily understood that many modifications may be made in the exemplary embodiments without departing substantially from the novel teachings and advantages of the present invention. Therefore, the scope of the claims should not be limited to the exemplary embodiments, but should be given the broadest interpretation consistent with the entirety of the specification. Therefore, the present invention may be modified without departing from the spirit and essence of the present invention as defined in the appended claims.
Claims
1. A method for producing a disinfectant product comprising a bioactive bacteriophage that is infectious to a predetermined bacterium, the disinfectant product being usable in a target environment, the method include: - providing an initial product wherein the bioactive bacteriophage is present in an initial amount, and at least partially protecting the bioactive bacteriophage from supercritical carbon dioxide scCO by at least one of freeze-drying the bioactive bacteriophage, immobilizing the bioactive bacteriophage on a polymer, and encapsulating the bioactive bacteriophage in a microcapsule within a hydrophobic layer. 2 degradation; as well as - contacting the initial product with a sterilization fluid under sterilization conditions for a sterilization duration of between 30 min and 120 min, to produce the sterilized product from the initial product, the sterilization fluid comprising scCO at a pressure between 8 MPa and 11 MPa 2 , and wherein the sterilizing fluid is at a temperature between 31° C. and 38° C.; - wherein the biologically active bacteriophage is present in the disinfection product in a final amount effective to produce lysis of the predetermined bacteria to reduce the bacterial content in the target environment when the disinfection product is used in the target environment.
2. The method of claim 1, wherein the sterilized product is substantially free of bacterial contamination.
3. The method of claim 1, wherein the disinfectant product is substantially free of microorganisms other than biologically active bacteriophages.
4. The method of claim 1, wherein protecting the biologically active bacteriophage comprises lyophilizing the biologically active bacteriophage.
5. The method of claim 4, wherein protecting the biologically active bacteriophage comprises encapsulating the biologically active bacteriophage in microcapsules.
6. The method of claim 5, wherein the microcapsules encapsulate the biologically active bacteriophage within a hydrophobic layer.
7. The method of claim 5, wherein the microcapsules encapsulate the biologically active bacteriophage within a polymer.
8. The method of claim 1, wherein protecting the biologically active bacteriophage comprises dispersing the biologically active bacteriophage within a polymer layer.
9. The method of claim 1, wherein protecting the biologically active bacteriophage comprises immobilizing the biologically active bacteriophage on a polymer.
10. The method of claim 9, wherein protecting the biologically active bacteriophage comprises adsorbing the biologically active bacteriophage on the polymer.
11. The method according to any one of claims 7 to 10, wherein the polymer layer is hydrophobic.
12. The method according to claim 11, wherein the polymer is selected from (1) poly(esteramide urea) wherein at least one diol, at least one diacid and at least one amino acid are linked together by ester bonds, amide bonds and urea bonds, (2) poly(ester polyurethane urea) wherein at least one diol and at least one amino acid are linked together by ester bonds, polyurethane bonds and urea bonds, (3) poly(esteramide polyurethaneurea) wherein at least one diol, at least one diacid and at least one amino acid are linked together by ester bonds, amide bonds, polyurethane bonds and urea bonds, (4) poly(esteramide polyurethane) wherein at least one diol, at least one diacid and at least one amino acid are linked together by ester bonds, amide bonds and polyurethane bonds, (5) poly(ester urea) wherein at least one diol and at least one amino acid are linked together by ester bonds and urea bonds, and (6) poly(ester polyurethane) wherein at least one diol and at least one amino acid are linked together via ester bonds and polyurethane bonds, Further - the at least one diol is a compound of the formula: HO-R 1 -OH, R 1 Selected from C optionally interrupted by at least one oxygen 2 -C 12 Alkylene, C 3 -C 8 Cycloalkylene, C 3 -C 10 Cycloalkyl alkylene, - the at least one diacid is a compound of the formula: HO-(CO)-R 3 -(CO)-OH, R 3 It is C 2 -C 12 Alkylene, - The at least one amino acid is selected from naturally occurring amino acids and non-naturally occurring amino acids.
13. The method of claim 12, wherein the polymer is a poly(esteramide urea) comprising the following two randomly distributed blocks: in -l:m ratio ranges from 0.05:0.95 to 0.95:0.05, l+m=1, -R 1 Selected from C optionally interrupted by at least one oxygen 2 -C 12 Alkylene, C 3 -C 8 Cycloalkylene, C 3 -C 10 Cycloalkyl alkylene, -R 3 It is C 2 -C 12 Alkylene, -R 2 and R 4 are independently selected from the side chains of L-amino acids and D-amino acids such that R 2 or R 4 The attached carbon has either L or D chirality.
14. The method according to claim 13, wherein R 1 Yes-(CH 2 ) 6 -, R 3 Yes-(CH 2 ) 8 -, and R 2 and R 4 They are all side chains of L-leucine.
15. The method of any one of claims 1 to 10, wherein the sterilizing fluid comprises at least 99.9% scCO 2 .
16. The method of any one of claims 1 to 10, wherein the disinfecting fluid is substantially free of water.
17. The method according to any one of claims 1 to 10, wherein the scCO 2 In addition, the disinfecting fluid also contains a bactericide additive.
18. The method of claim 17, wherein the biocide additive is suitable for increasing CO 2 Permeation across bacterial cell membranes.
19. The method of claim 17, wherein the biocide additive has acidic properties; oxidizing properties; or both acidic and oxidizing properties.
20. The method of claim 17, wherein the biocide additive is selected from the group consisting of acetic acid, t-butyl hydroxyperoxide, peracetic acid, ethanol, formic acid, and hydrogen peroxide.
21. The method of claim 17, wherein the disinfecting fluid comprises between 0.2% and 10% per volume of the biocide additive.
22. The method of claim 17, wherein the disinfecting fluid comprises between 0.5% and 2% per volume of the biocide additive.
23. The method according to any one of claims 1 to 10, wherein the method reduces the phage titer of the biologically active phage in the phage-containing fraction of the initial product by up to 100-fold such that the final amount is at least 1% of the initial amount.
24. The method of claim 23, wherein the method reduces the phage titer of the biologically active phage in the phage-containing portion of the initial product by up to 10-fold such that the final amount is at least 10% of the initial amount.
25. A method of eliminating or reducing bacterial contamination of a product comprising a composition containing bacteriophage, the method comprising exposing the product to supercritical carbon dioxide (scCO) 2 wherein the composition comprising bacteriophage is exposed to scCO 2 and then comprising biologically active bacteriophage, and wherein the composition containing bacteriophage comprises at least one of bacteriophage dispersed in a polymer and bacteriophage immobilized on a polymer and is heated to 9 MPa and 10 MPa at 31° C. and 38° C. with scCO 2 The phage-containing composition is treated for between 30 min and 120 min.
26. The method of claim 25, wherein the phage-containing composition comprises phage in solution.
27. The method of claim 25, wherein the composition containing bacteriophage comprises lyophilized bacteriophage.
28. The method of claim 25, wherein the bacteriophage-containing composition comprises bacteriophage dispersed in a polymer.
29. The method of claim 25, wherein the phage-containing composition comprises phage immobilized on a polymer.
30. The method of claim 25, wherein the composition comprising bacteriophage comprises bacteriophage adsorbed, adhered or otherwise immobilized on a surface.
31. The method of claim 30, wherein the product is an implant for implantation in a human or animal body and the surface is an exposed surface of the implant.
32. The method according to any one of claims 25 to 31, wherein the scCO 2 The phage-containing composition is additionally treated with a bactericide additive.
33. The method of claim 32, wherein the biocide additive and the scCO 2 The composition comprising the bacteriophage is treated.
34. The method of claim 32, wherein the biocide additive is suitable for increasing CO 2 Permeation across the bacterial cell membrane.
35. The method of claim 32, wherein the biocide additive has acidic properties; oxidizing properties; or both acidic and oxidizing properties.
36. The method of claim 32, wherein the biocide additive is selected from the group consisting of acetic acid, t-butyl hydroxyperoxide, peracetic acid, ethanol, formic acid, and hydrogen peroxide.
37. A disinfection product obtained by the method according to any one of claims 1 to 24, the disinfection product can be used in a target environment to control the growth of predetermined bacteria in the target environment, the disinfection product comprising: a biologically active bacteriophage that is infectious to the predetermined bacteria.
38. A sanitized product according to claim 37, wherein the sanitized product is substantially free of bacterial contamination.
39. A disinfectant product according to claim 37 or 38, wherein the disinfectant product is selected from the group consisting of a polymer patch, a suspension of polymer microcapsules, an implant comprising a surface coated with a polymer and a powder composition comprising freeze-dried bacteriophage.
40. A method for controlling the growth of predetermined bacteria in a target environment using a biologically active bacteriophage that is infectious to the predetermined bacteria, the method include: The disinfection product according to any one of claims 37 to 39 is brought into contact with the predetermined bacteria in the target environment and lysis of the predetermined bacteria is produced using the biologically active bacteriophage.
